Irkutsk anti-plague institute death prompts quarantines and conflicting official accounts.
|Videos|June 12, 2020
Contagion Live News Network: Fauci Expresses COVID-19 Recovery Caution
Author(s)Contagion® Editorial Staff
Trending infectious disease news.
Advertisement
Hello and welcome to Contagion.
In a recent interview, Dr. Anthony Fauci, head of the NIAID, expressed caution about the upcoming few weeks as stay-at-home orders are relaxed. Fauci said that while he understands people’s need for normalcy and getting the economy back up and running, he also warns everyone to not simply throw caution to the wind. “
In other coronavirus news, a Harvard Medical School study team used national survey results to identify individuals at elevated risk for severe COVID-19 and, among them, those at high risk of financial ruin as a result of costs associated with their care.
And lastly, Moderna announced scaling up of manufacturing capacity for its investigational messenger RNA COVID-19 vaccine. Infectious disease experts have recommended that stockpiles of several promising vaccine candidates be created as they enter late stage development.
For Contagion, I’m Grant Gallagher. Thanks for watching.
Advertisement
Related to this article
A laboratory technician at a Siberian anti-plague institute has died of pneumonia of unknown cause, prompting quarantines and contact monitoring while Russian officials stop short of confirming plague.
A study finding clesrovimab comparable to palivizumab in protecting at-risk infants in their first RSV season was extended to demonstrate clesrovimab effective and well-tolerated when administered in their second season.
Lori Handy, MD, provides guidance in these areas including presentation before rash onset, when patients should be considered for the inpatient setting, and what treatment looks like.
Jason Pogue, PharmD, BCPS, BCIDP, contextualizes preliminary data looking at this trial and other extended-spectrum beta-lactamase (ESBL) studies, which reopens the debate around carbapenem-sparing treatment options.
In the phase 3 LIBERTY study, the investigational monoclonal antibody, VYD2311, had significantly fewer adverse events than an mRNA COVID-19 vaccine, and it did not blunt vaccine-induced neutralizing titers when the two were given together.
With a significant increase in rabies exposures this year, Rodney Rohde, PhD, talks about seeking medical attention after animal interactions as well as clinical treatment when people have been bit or scratched.
In the first episode of our new series looking at the food safety network, Lynette Johnston, PhD, offers insights into how the federal government surveillance infrastructure operates and how epidemiologists serve as food detectives in determining bacterial pathogens and potential foodborne outbreaks.
Advertisement
Advertisement